Onkológia 4/2021

The role of PARP inhibitors in the treatment of ovarian cancer

PARP inhibitors are very promising in the treatment of ovarian cancers. For the indication of PARP inhibitors as maintenance treatment in patients with ovarian cancer, it is important to know the BRCA status and an important parameter is platinum-sensitivity. In 2014, PARP inhibitors were approved worldwide as maintenance treatment for platinum-sensitive recurrent ovarian cancer after several lines of chemotherapy. In the last decade, the indication for three PARP inhibitors (olaparib, niraparib and rucaparib) has been approved as maintenance treatment for recurrent ovarian cancer. At the end of 2020, based on the conclusions of phase III clinical trials - SOLO-1, PRIMA (patients without BRCA mutations present) were also included) and PAOLA-1, maintenance treatment with a PARP inhibitor was approved in newly diagnosed ovarian cancer with BRCA mutations present. Olaparib, the first PARP inhibitor, has been approved as maintenance therapy in patients with newly diagnosed advanced ovarian cancer with BRCA mutations. It represents a new therapeutic standard.

Keywords: ovarian cancer, PARP inhibitors, olaparib, niraparib, rucaparib, mutation of BRCA